(EMAILWIRE.COM, November 29, 2011 ) Dallas, TX MARINA BIOTECH INCORPORATED (NASDAQ: MRNA) "Up 29.64% in morning trading"

Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients.

MAGAL SECURITY SYSTEMS LIMITED (NASDAQ: MAGS) "Up 34.34% in morning trading"

Magal S3 is a leading international provider of security, safety and site management solutions and products. Over the past 40 years, Magal S3 has delivered tailor-made solutions to hundreds of satisfied customers in over 80 countries. Magal S3 offers a broad portfolio of unique products used to protect sensitive installations in some of the world's most demanding locations and harshest climates. This portfolio covers the following three categories:

* Perimeter Intrusion Detection Systems (PIDS) a variety of smart barriers and fences, fence mounted detectors, virtual gates, buried and concealed detection systems.

* Close Circuit TV (CCTV) a comprehensive management platform with a leading Intelligent Video Analysis (IVA) and Video Motion Detection (VMD) engine.

* Physical Security Information Management (PSIM) an open site management system that enhances command, control and decision making during both routine operations and crisis situations

CENTRAL EUROPEAN DISTRIBUTION CORPORATION (NASDAQ: CEDC) "Up 29.38% in morning trading"
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. Poniard's lead product candidate is picoplatin, a new generation platinum-based cancer therapy designed to treat solid tumors that are resistant to existing platinum-based therapies. Assuming receipt of shareholder approvals and satisfaction of other conditions to closing, the merger of Poniard and ALLOZYNE, Inc. will result in a Nasdaq-listed specialty pharmaceutical company focused on developing and commercializing therapeutics in the areas of autoimmune and inflammatory disease and cancer. The combined company is expected to seek a partnership for the continued development of picoplatin.

About OTCPicks.com

OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.

The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily stock alerts go to http://www.otcpicks.com to sign up.

Disclosure: OTCPicks.com and affiliates have been not been compensated by any of the companies covered in this release.


OTCPicks.com
Brian Dean
972-546-3740
publisher@otcpicks.com


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.


Source: EmailWire.Com